- After submitting a written response to the FDA's request for additional information on Meridian Bioscience Inc's (NASDAQ: VIVO) Revogene SARS-CoV-2 test on February 16 and further discussions with the FDA, the company decided to withdraw its Emergency Use Authorization (EUA) application.
- The company plans to conduct a new clinical validation study and a Limit-of-Detection bridging study, with potential re-submission of a EUA application during Q3 of 2021.
- Price Action: VIVO is down 3.39% at $22.23 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
